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Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system 
characterized by focal demyelination patches associated with inflammatory infiltrates 
containing T lymphocytes. For decades, CD4+ T cells have been recognized as playing a 
major role in the disease, especially in animal models, which has led to the development 
of several therapies. However, interest has recently developed in the involvement of CD8+ 
T cells in MS following the analysis of infiltrating T cells in human brain lesions. A broad 
range of evidence now suggests that the pathological role of this T cell subset in MS 
may have been underestimated. In this review, we summarize the literature implicating 
CD8+ T cells in the pathophysiology of MS. We present data from studies in the fields of 
genetics, anatomopathology and immunology, mainly in humans but also in animal mod-
els of MS. Altogether, this strongly suggests that CD8+ T cells may be major effectors in 
the disease process, and that the development of treatments specifically targeting this 
subset would be germane.
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iNTRODUCTiON
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), 
resulting in disability. The clinical manifestations are very variable, and include motor, sensory, 
visual, and cognitive symptoms, none of them being disease specific (1). The disease is thought to be 
a result of both genetic and environmental factors, including infectious agents, vitamin D deficiency, 
obesity, and smoking (2). Neuropathological studies show disseminated patches of demyelination 
among the brain and the spinal cord, resulting in altered nerve conduction. Axonal loss can also be 
observed. Demyelinated patches are characterized by immune cell infiltration, which is absent in 
normal brain tissue. The infiltrate is mainly composed of macrophages, and, to a lesser extent, T and 
B lymphocytes (1, 3, 4).
In addition to the immune cell infiltrates, a wide range of evidence points to the pivotal role 
of the immune system in the development of the disease. Indeed, the genetic variants conferring 
a higher susceptibility to MS are associated to immune mechanisms, the animal models used 
for disease characterization and comprehension are autoimmune ones, and current treatments 
Abbreviations: BBB, blood–brain barrier; CNS, central nervous system; CSF, cerebrospinal fluid; EAE, experimental autoim-
mune encephalomyelitis; EBV, Epstein–Barr virus; HLA, human leukocyte antigen; HV, healthy volunteers; MAIT, mucosal-
associated invariant T; MBP, myelin basic protein; MHC, major histocompatibility complex; MRI, magnetic resonance imaging; 
MS, multiple sclerosis; NAWM, normal-appearing white matter; TCR, T-cell receptor.
TABLe 1 | MHC-i alleles and their additive effect on MS risk with MHC-ii 
alleles.









MHC alleles described as implicated in MS risk are listed with their corresponding risk 
factor expressed by odds ratio. These data are from Fogdell-Hahn et al. and Harbo 
et al. (16, 17).
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regulate or modulate the immune system (1). For decades, MS 
has been considered as being driven by CD4+ T cells, especially 
in animal models of the disease (1). However, treatment with 
monoclonal anti-CD4 antibody in phase II trials failed to reduce 
MS activity [measured by magnetic resonance imaging (MRI)] 
(5). In recent years, numerous other immune populations have 
been shown to be important in MS development. Among these, 
CD8+ T cells have appeared as potential major effectors within 
the CNS, especially in studies using human samples. In this 
review, we will focus on the various results that seem pivotal in 
understanding the involvement of CD8+ T cells in the patho-
physiology of MS. The potential regulatory role of CD8+ T cells 
in the disease will be described elsewhere in this issue [for other 
reviews, see Ref. (6, 7)].
MHC CLASS i GeNeS’ iMPACT ON MS 
RiSK
Numerous alleles associated with immune response have been 
found to be linked with increased MS risk (8–12). The strongest 
association, with an odds ratio of 3, was seen for human leuko-
cyte antigen (HLA)-DRB1*15:01 in European and United States 
populations, which identifies CD4+ T cells as potent effectors in 
the disease (13). Major histocompatibility complex (MHC) class I 
alleles are also associated with MS, though to a lesser extent. HLA-
A3 and B7 alleles were the first to be described as associated with a 
higher risk of developing the disease (14, 15). More recently, HLA 
A*0301 was associated with a higher risk (2×) and HLA A*0201 
with a protective effect (50%) (16, 17). These associations were 
confirmed by Friese and colleagues in “humanized” transgenic 
mice for HLA*0301 and/or HLA-A*0201. These mice either 
developed (HLA*0301) or were protected from (HLA*0201) the 
disease after proteolipid protein (PLP) injection (18). In addition, 
these alleles are known to work in synergy with MHC class-II 
alleles, such as DRB1*1501, resulting in an increased risk when 
both are present (16). These data strongly suggest that some CD8+ 
T cells may have a beneficial or pathogenic effect, depending on 
the genetic background (Table 1). On top of this genetic evidence, 
the presence of CD8+ T cells in MS lesions, as well as their cyto-
toxic profile, evinces their involvement in the disease.
CD8+ T CeLLS ARe PReSeNT AND HAve 
A PATHOGeNiC PROFiLe iN THe MS CNS
CD8+ T Cell infiltration in CNS Lesions
One of the major indicators pointing toward an implication of 
CD8+ T cells in the pathophysiology of MS is the presence of these 
cells, in a greater number than CD4+ T cells, in the brain lesions of 
MS patients. The fact that CD8+ T cells outnumber CD4+ T cells 
in MS lesions was first observed in the 80s, in particular in the 
parenchyma, and was regardless of differing clinical parameters, 
such as disease duration, disease evolution, and therapy (19). 
In 1986, Hauser et  al. studied 16 cases of progressive MS, and 
observed up to 50 times more CD8+ T cells in both the paren-
chyma and in perivascular cuffs of active lesions, with no case of 
more CD4+ than CD8+ T cells. CD8+ T cells also predominated 
in normal-appearing white matter (NAWM) (20). Recently, our 
study of 22 lesions in three MS patients found the same, CD8+ 
T cells being predominant regardless of the lesion type studied 
(21). Other studies have reached the same conclusion by single 
cell analysis in different MS patients (22–24). Although not all 
the studies concur with the above (25), others put forward the 
hypothesis that CD8+ T cells might be more prevalent in the 
parenchyma while CD4+ T cells would stay in the perivascular 
areas (26). Recently, in tissue block section of MS patients, CD8+ 
T cells were described as being often present in cortical plaques 
(54 of 70 cortical plaques analyzed). This type of plaque has been 
found to be associated with disease progression and cognitive 
impairment in the early stages of MS (27).
MHC-i expression and CNS Damage
MHC-I expression and presentation is necessary for CD8+ T cells 
to carry out their cytotoxic functions. In 2004, a study includ-
ing 30 MS patients and 21 controls quantified the expression of 
MHC-I on various cell subtypes within the CNS by immunohis-
tochemistry and fluorescence methods (28). While constitutive 
expression of MHC-I on macrophages/microglia and endothelial 
cells was observed, MHC-I expression was gradually upregulated 
on astrocytes, oligodendrocytes, neurons, and axons depending 
on the disease type (inactive, chronic active, and active MS) and 
lesion activity (inactive, periplaque white matter, and active), 
making these cells potential targets for CD8+ T cells in the 
context of the disease. Consistent with this, CD8+ T cells have 
been shown to be able to mediate axonal transection in vitro (29). 
In this study, murine neurons induced to express MHC-I were 
pulsed with a dominant peptide of the lymphochoriomeningitis 
virus envelope glycoprotein (GP33). Five to 30 min after culture 
with antigen-specific cytotoxic CD8+ T cells, neurite breakage 
appeared in contact zones between CD8+ T cells and neurites. 
Confocal live imaging gave a clear image of this process. Axonal 
transection has also been suggested in MS (30). Indeed, axonal 
injury, in 88 brain biopsy samples from 42 patients, correlated 
with the number of CD8+ T cells, but not CD3+ T cells, found in 
the lesions (31). Variable proportions of lesion-infiltrating CD8+ 
T cells express granzyme B [Figure 1, personal results from Ref. 
(21)] and interferon γ (IFNγ), further evincing the ability of 
these cells to damage the CNS (21, 25, 32). In conclusion, CD8+ 
FiGURe 1 | infiltrating T cells are mainly CD8+ T cells and express GZM-B. Example of staining with DAPI (blue), CD3 (red), CD8 (gray), and GZM-B (green). 
The line in the pictures indicates 20 μm. Stars show CD3+CD8+GZM-B+ and arrows show CD3+CD8−GZM-B− cells. GZM-B: granzyme-B. From personal data.
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T cells seem more likely than CD4+ T cells to mediate CNS dam-
age, in particular through their cytotoxic and proinflammatory 
properties.
Pathogenic CD8+ T Cells in the CSF
Deciphering the mechanisms involved in MS development is 
made difficult by the limited access to the CNS compartment. 
As such, a lot of studies focus on the cerebrospinal fluid (CSF) as 
a surrogate compartment for understanding the T cell processes 
occurring in  situ. In 2007, an enrichment of effector memory 
CD8+ T cells in the CSF of 52 relapsing–remitting MS patients 
was observed at the beginning of the disease (33). This, together 
with an enrichment of granzyme B-expressing CD8+ T cells, has 
been confirmed in 17 other relapsing-remitting patients (25). 
Interestingly, the effector memory CD8+ T cells had increased 
in vitro migration through a model of the blood–brain barrier, 
especially those producing granzyme B, perforin, IFNγ, and 
interleukin 17 (IL-17). This was further confirmed in a mouse 
experimental autoimmune encephalomyelitis (EAE) model (25). 
Another study found that granzyme A and B levels were higher 
in the CSF of patients in flare up, compared to those in clinical 
remission and control patients (34). Altogether, these results 
suggest a specific enrichment of effector memory CD8+ T cells in 
the CNS compartment in MS and place them as disease effectors.
CD8+ T Cell Migration into the Brain
Studying the mechanisms leading to CD8+ T cell transmigra-
tion into the CNS further highlights their involvement in the 
disease process. Blockade of α4 integrin in EAE mice immunized 
with myelin oligodendrocyte glycoprotein (MOG)35–55 yields a 
decreased number of infiltrating CD8+ T cells, together with a 
reduced EAE score. However, a similar effect has been described 
for CD4+ T cells (25). More recently, melanoma cell adhesion 
molecule (MCAM), expressed by a subset of human effector 
CD8+ T cells, was reported to be upregulated during MS relapse 
compared to controls (35). Interestingly, MCAM blockade 
prevents the transmigration of human CD8+ T cells across a 
blood–brain barrier (BBB) model and decreases the EAE score 
in active, transfer and spontaneous models (36–38). As MCAM 
binds itself and laminin 411 (37), which are both expressed by 
endothelial cells, the mode of action of MCAM blockade is not 
yet known (35). P-glycoprotein (also known as multidrug resist-
ance protein 1), a transporter involved in drug efflux (39) and 
in cytokine/chemokine secretion (40), has also been shown to 
be important for the trafficking of CD8+ T cells into the brain 
during the disease. Indeed, Mdr1a/b KO mice show significantly 
reduced EAE (40). In another study, P-glycoprotein silencing 
led to decreased CD8 infiltration into the brain, with no effect 
on CD4+ T cells (41). P-glycoprotein control of endothelial C–C 
chemokine ligand 2 (CCL2) secretion was responsible for this 
result. Indeed, EAE mice lacking this protein or CCL2 show 
significantly reduced CD8+ migration into the brain. More sig-
nificantly, CCL2 transcript has also been found to be elevated in 
six MS lesions compared to six controls (41).
In conclusion, various studies on brain, spinal cord, and CSF, 
as well as on the mechanisms allowing T cell entry into the 
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brain highlight CD8+ T cells’ potential role in the development 
of MS.
CD8+ T CeLL RePeRTOiRe AND 
ReACTiviTY iN MS
A number of studies have focused on the T cell pools that arise 
with MS in order to understand their role in its pathophysiol-
ogy. Different CNS and non-CNS antigens have been used to 
search for autoreactive T cells (3, 42), but to date the triggering 
antigen(s) is unknown. The search for a specific antigen is made 
more difficult because of the mechanisms of molecular mimicry, 
epitope spreading, bystander activation, and/or dual T cell 
receptor (TCR) (43–48). Numerous studies have analyzed the 
T cell repertoire, allowing the identification of reactive T cells 
without the need to know the recognized antigen. Indeed, after 
antigen recognition, T cells undergo clonal proliferation, and this 
expanded T cell population can be identified within the total T 
cell pool.
CD8+ T Cell Repertoire in Lesions and in 
CSF
Two different groups, including our own, have studied the 
TCR repertoire of lesion-infiltrating T cells, either by single cell 
analysis (22, 23) or by whole TCR analysis using high-throughput 
sequencing, in comparison with sorted populations from the 
blood (21). These studies show that infiltrating CD8+ T cells are 
oligoclonal, i.e., only clones bearing particular TCRs specific to 
each patient are represented within the lesion, which is less the 
case for CD4+ T cells. These oligoclonal CD8+ T cells are also 
found in different locations in the brains of the same patients. In 
addition, some of these clones harbored silent mutations (23). 
These data strongly suggest antigen-driven selection or activation 
processes, and identify these infiltrating CD8+ T cells as disease 
effectors.
CD8+ T Cell Repertoire Alteration in CSF 
and Blood
Different studies have observed that the blood of MS patients 
exhibits more clonal expansions than that of controls (49–53). 
In 35 patients, our group showed that the repertoire was more 
skewed in the CD8 than in the CD4 compartment, further sug-
gesting the involvement of CD8+ T cells (50). The repertoire was 
even more skewed in the CSF than the blood of MS patients, espe-
cially in CD8+ T cells which interestingly expressed memory T 
cell markers (54–56). Of note, clonal expansions were correlated 
to the clinical activity of the disease. We observed more blood 
expansions in MS patients with an active form of the disease, 
assessed by MRI (57). Muraro et al. published a case study that 
extensively studied the TCR Vβ repertoire in the CSF of one MS 
patient, and described more expansions in that compartment 
during relapse than during remission (58). Altogether, these data 
strongly suggest an implication of oligoclonal T cells, especially 
CD8+ T cells, in the pathophysiology of MS.
However, whether expanded T cells in blood and CSF correlates 
with T cell expansion in the CNS, which is likely to participate 
in disease development, was unknown until recently. Indeed, 
only one study had suggested that some expanded CNS CD8+ T 
cell clones could persist in the blood and in the CSF for several 
years, seen in two MS patients (24). Very recently, we confirmed 
and extended this result by comparing the TCR repertoires in 
the blood, CSF, and CNS (22 lesions with various locations and 
activities) of three MS patients (21). Using CDR3 spectratyping 
and high-throughput sequencing, we showed for the first time 
that the CSF repertoire mirrors that of the CNS, which is, to a 
lesser extent, also similar to that of blood CD8+ T cells. This fur-
ther evinces the involvement of CSF and blood expanded CD8+ 
T cells in MS and further identifies CSF expanded T cells as good 
surrogates for infiltrating T cells.
CD8+ T Cell Autoreactivity
A number of studies have been looking at autoreactive T cells 
in MS, using different methods and antigens, but the results are 
hardly comparable between the studies and no consensus has been 
found as to the presence of CNS-specific CD4+ or CD8+ T cells 
in MS patients [reviewed in Ref. (42)]. In 2004, Crawford et al. 
adapted a flow cytometry approach to analyze antigen-specific 
CD4+ and CD8+ T cell proliferative response in MS patients. 
They showed that relapsing–remitting MS patients have a higher 
proportion of CD8+ T cell responses against CNS peptides 
compared to healthy volunteers (HV) or primary progressive MS 
patients and that this is not the case for CD4+ T cells (59). In 
another study, CD8+ T cells specific to apoptotic epitopes have 
been shown to be overrepresented in MS patients (in a cohort of 
26 compared to 27 HV), and to be able to produce IFNγ and/or 
IL-17 when stimulated with apoptotic epitopes (60). Interestingly, 
these cells have been found also in the CSF and correlate with the 
level of disease disability, which strongly suggests their involve-
ment in the immunopathology (60). Finally, Zang et al. tested the 
proliferation of CD8+ T cells in contact with irradiated PBMC 
incubated with degenerated myelin basic proteins (MBP), show-
ing that autoreactive CD8+ T cells recognizing MBP proteins were 
increased in the blood (15 MS patients compared to 15 HV) (61). 
Recently, high-throughput sequencing on paired blood and CSF 
samples of MS patients and control gave further evidence of the 
implication of a particular subset of CD8+ T cells in MS (62), a 
specific enrichment of Epstein–Barr virus (EBV)-specific CD8+ T 
cells being observed in the CSF of MS patients.
These results evince the existence of a pool of CD8+ T cells able 
to damage the CNS, however the triggering events as well as the 
antigens recognized remain unclear, necessitating the develop-
ment of other methods in order to isolate and study the relevant 
T cells.
ANiMAL MODeLS iDeNTiFY CD8+ T 
CeLLS AS POTeNT eFFeCTORS iN THe 
DiSeASe
Prior to 2001, most models focused on the involvement of CD4+ T 
cells in the development of EAE. Two groups, developed, in paral-
lel, EAE models based on specific CD8+ T cell adoptive transfer. 
First, in mice C57BL/6, Sun et  al. observed that the adoptive 
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transfer of pMOG35–55 CD8+ T cells led to the development of 
an EAE that was both longer and more severe than the disease 
actively induced by the injection of the MOG35–55 peptide (63). 
EAE did not develop in mice lacking β2 microglobulin, further 
supporting the involvement of CD8+ T cells in the development 
of the disease (63). These data were confirmed in 2005, and the 
authors further identified the pMOG37–46 peptide as the minimal 
peptide recognized by the pMOG35–55-specific CD8+ T cells that 
both led to IFNγ production by these cells and to the develop-
ment of severe EAE (64). In another 2001 study, Huseby et  al. 
showed that a rapid and severe CNS-autoimmune disease could 
be induced in C3H mice after adoptive transfer of CD8+ T cells 
lines reacting against the MBP79–87 peptide (65). The severity of 
the disease was reduced when coinjecting anti-IFNγ with the 
CD8 MBP-specific cell lines, supporting a pivotal role for this 
cytokine in the development of the disease. Interestingly, the 
clinical symptoms, as well as the CNS lesion types and distribu-
tions observed, were different from those induced after CD4+ T 
cell transfer, better reflecting the clinical features of the human 
disease (65). The authors then proposed that the different MS 
clinical manifestations could be linked to the activation of either 
CD4+ or CD8+ T cells. Since then, CD8+ specific models have 
mainly been developed by transfer of T cells bearing TCR recog-
nizing transgenic epitopes expressed on oligodendrocytes (66). 
In 2008, Saxena et  al. developed a double knock-in transgenic 
mouse in which the influenza hemagglutinin (HA) expression 
was restricted to oligodendrocytes (67). The injection of in vitro 
activated CD8+ T cells bearing a TCR specific for HA led to 
CNS inflammation and demyelination. Of note, the activated 
CD8+ T cells produced granzyme B and IFNγ and exhibited 
cytotoxicity against cells loaded with HA in  vitro. The authors 
were able to track these cells in the lesions, in close proximity 
to oligodendrocytes and in association with microglia activation. 
In another study, Na et al. showed that double transgenic mice 
with ovalbumin (OVA) expression in oligodendrocytes and 
OVA-specific TCR CD8+ T cells (OT-I) – but not OVA-specific 
TCR CD4+ T cells (OT-II) – develop a spontaneous EAE with 
demylinated and infiltrated lesions (68). The disease developed 
during the first 10–12 days of life, when CD8+ T cells still have 
access to the CNS, and was amplified by IFNγ. Of note, block-
ing the recognition of the OT-I CD8+ T cells with an antibody 
specific for the OVA-peptide/MHC-I complex prevents disease 
development (69). Interestingly, most of these models develop 
either clinical manifestations and/or infiltration characteristics 
that have a greater resemblance to MS symptoms and infiltrates 
than CD4-mediated EAE models (65, 67, 68).
Another model has been used to study the mechanisms by 
which CD8+ T cell infiltrate and damage the CNS. In Theiler’s 
murine encephalomyelitis virus (TMEV)-infected mice, the viral 
model of MS, CD8+ T cells secreting perforin were shown to be 
involved in BBB disruption and astrocyte activation (70). CD8+ T 
cells have also been shown to be able to enter the CNS in a naïve 
CL4 mice model without peripheral activation (CD8+ T cells 
specific for HA). Even if they remained inactivated in situ, they 
were able to proliferate when HA was injected intracerebrally. 
Interestingly, blocking MHC-I led to the reduction by 76% of 
the trafficking (71). Recently, Sobottka et  al. further described 
mechanisms of presentation into the CNS. Using living brain 
slices preincubated with IFNγ (to mimic CNS inflammation) 
and OVA, they showed that OT-I CD8+ T cells (OVA-specific) 
were able to mediate axonal damage. Moreover, they obtained the 
same results using transgenic oligodendrocytes-expressing OVA 
in their living brain slices, making them potential target cells for 
CD8+ T cell pathogenicity (72).
Animal models depending on CD8+ T cells are, thus, relatively 
recent, and their study may shed new light on the mechanisms 
involving these cells in disease development (Table 2).
iL-17-PRODUCiNG CD8+ T CeLLS AS 
POTeNT eFFeCTORS iN MS
Similarly to CD4+ T cells, the implication of IL-17-producing 
CD8+ T cells in MS has been recently suggested. The first study 
suggesting this was performed on 18 frozen CNS samples from 14 
MS patients (26). Seventy to 80% of the infiltrating T cells, both 
CD4+ and CD8+ T cells, expressed IL-17 in active and chronic 
active lesions, shown through double immunofluorescent stain-
ing. This percentage was dramatically lower, at 20%, in chronic 
inactive lesions and NAWM, suggesting significant involvement 
of these IL-17-producing CD4 and CD8+ T cells in MS patho-
genesis. After in  vitro stimulation of blood samples, another 
study observed more IL-17 producing CD8+ T cells in the 20 MS 
patients than in the 16 controls (74). CD8+ T cells secreting IL-17 
after in vitro stimulation were present in greater frequency in the 
CSF than in the blood of 17 MS patients in the early stages of 
the disease (75). Finally, in EAE, IL-17-producing CD8+ T cells 
were found to be necessary for IL-17-producing CD4+ T cell 
accumulation in the CNS and for disease development (75).
In human, the in  vitro production of IL-17 is restricted to 
CD161-expressing cells (76). These cells have been shown to 
be present in CNS lesions of MS patients and the majority of 
them produce IFNγ (IL-17 staining was not performed on these 
samples) (32). In addition, an enrichment of CD8+CD161hi in 
the blood of MS patients has also been evidenced, suggesting a 
specific involvement in the disease (32).
Recently, it has been shown that more than 80% of these cells 
are mucosal-associated invariant T (MAIT) cells. MAIT cells are a 
subset of innate effector memory T cells bearing a semi-invariant 
TCR (Vα7.2-Jα33/12/20) in humans (77–82). They are restricted 
to the MHC class-I related protein I (MR1) and have antimicro-
bial properties both in vitro and in vivo (83–86). Although they 
have been correlated with various autoimmune diseases (87–90), 
their implication, especially in MS (32, 91, 92), remain elusive. 
MAIT cells are present in the CNS of MS patients, but at very 
low frequencies compared to in the blood (92–94). This argues 
against a particular implication of this IL-17-producing CD8+ 
T cell subset in the pathophysiology of MS (92, 95), similar to 
what has been described for psoriasis, where conventional IL-17-
producing CD8+ T cells might be more pathogenic than MAIT 
cells (87).
Other IL-17-producing CD8+ T cell subsets have been 
described (96), with different markers, such as MCAM (97), but 
further research is necessary to decipher their involvement in MS 
pathogenesis.
TABLe 2 | Summary of eAe models used to study CD8+ T cells.
Model Mode Background Results Publication
WT MOG35–55 CD8+ injection WT (C57BL/6) Severe and permanent EAE (63)
MBP79–87 CD8+ injection WT (C3H) Severe EAE with similarities with MS 
features
(65)
MOG35–55 CD8+ injection WT (C57BL/6) Severe and long-term EAE (64)
Transgenic HA CD8+ injection Oligodendrocytes Tg for HA expression (CL4) CNS inflammation and demyelination (67)
OVA CD8+ injection Oligodendrocytes Tg for OVA expression (C57BL/6) Severe/lethal EAE (68)
“Humanized” 
transgenic
MOG35–55 + MOG181 injection HLA-A*0201 Tg (C57BL/6) More severe EAE than MOG35–55 alone (73)
PLP45–53 injection HLA-A*0201-2D1 TCR (specific for PLP45–53) double Tg 
(CBA/c × C57BL/6)
MS-like disease (relapsing–remitting) (18)
HA, hemagglutinin; OVA, ovalbumin; Tg, transgenic; MOG, myelin oligodendrocyte glycoprotein; MBP, myelin basic protein; PLP, proteolipid protein; EAE, experimental autoimmune 
encephalomyelitis; WT, wild type; CNS, central nervous system; MS, multiple sclerosis; TCR, T cell receptor.
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FiGURe 2 | Steps to elucidate to better understand CD8+ autoreactivity mechanisms in MS disease. A peripheral inflammation induced by pathogens 
(such as EBV) could occur in case of uncontrolled infection. This can lead to the activation or reactivation of CD8+ T cells, and the expression of several molecules 
implicated in adhesion, migration, and cytotoxicity, currently not well characterized. In this inflamed state, the BBB could overexpress adhesion and chimoattractant 
molecules, leading to the entry of CD8+ T cells into the CNS. In situ, CD8+ T cells could be reactivated by resident APC presenting target Ag(s), unknown for now. 
This could lead to the clonal expansion of CD8+ T cells along with the secretion of proinflammatory molecules. Finally, in this step, CD8+ T cells could be able to 
mediate damage to resident cells and axons potentially by the recognition of CNS derived peptides. Ag: antigen; GZM-B: granzyme-B; BBB: blood–brain barrier; 
CNS: central nervous system; MS: multiple sclerosis; EBV: Epstein–Barr virus; APC: antigen-presenting cell; TCR: T-cell receptor; MCAM: melanoma cell adhesion 
molecule; VCAM-1: vascular cell adhesion molecule 1; DC: dendritic cell; MHC-I: major histocompatibility complex I; CCR2: C–C chemokine receptor type 2; CCL2: 
C–C chemokine ligand 2; IFNγ: interferon γ; IL-17: interleukin-17.
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